Clinical impact of measurable residual disease in acute myeloid leukemia

HIGHLIGHTS

  • who: Tali Azenkot and Brian A. Jonas from the Department of Internal Medicine, University of California Davis School of Medicine, Medicine, University of California Davis School of Medicine, Sacramento, CA, USA have published the research: Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia, in the Journal: Cancers 2022, 14, 3634. of /2022/
  • future: More prospective randomized studies are needed to guide the application of MRD in the treatment of AML particularly in transplant.

SUMMARY

    In response to advances in MRD detection, quantification, and application in patient care, ELN and . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?